Miracor Medical Systems announced today the successful launch of its next-generation Pressure-Controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse System for the treatment of myocardial infarction. The new PICSO Impulse System, consisting of the Impulse Console and Impulse Balloon Catheters, is CE-marked and has already been used to treat patients in the U.K., Ireland and Hungary.
Infraredx Inc. today announced that it has entered into an agreement with HealthTrust, a group purchasing organization. Under the agreement, HealthTrust will offer the Infraredx TVC Imaging System, a novel dual-modality intravascular imaging technology, to its member network of 1,400 acute care facilities.
El Camino Hospital in Mountain View, California, became one of the first hospitals in California to adopt a new minimally invasive system to treat patients with narrowed, failing aortic heart valves who are considered to be at high risk to undergo surgery.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Annie Henderson, 69, suffers from multiple chronic ailments, including kidney failure and mitral valve insufficiency. The latter turned her life into a battle for breath, eliminating almost all activities and even making sleep a struggle. She couldn’t sleep for more than 20 minutes at a time without waking in a fit of coughing. Thanks to a leading-edge procedure performed at University of Texas (UT) Southwestern Medical Center, Mrs. Henderson is now breathing – and sleeping – easy.
Merit Medical Systems Inc. recently unveil its new ThinkRadial website and educational initiative at thinkradial.com.
The U.S Food and Drug Administration (FDA) cleared the EverFlex Self-Expanding Peripheral Stent System and outlined unsuitable candidates for the system.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Cephasonics today announced the introduction of the cQUB-1 (cQuest Ultrasound Box-1), the first product in a new family of cQUB white-label ultrasound systems designed and manufactured by Cephasonics for purchase by companies to rebrand with their own brand name and model number.
The quality and resolution of X-ray images depends on the characteristics of the focal point, the area that is struck by electrons and from which the resulting X-rays are emitted. A new ASTM International standard will allow users to determine the effective focal spot size of an X-ray source.
The U.S. Food and Drug Administration (FDA) approved the Sorin Freedom Solo and Solo Smart stentless heart valves from Sorin Group Canada Inc. to replace a diseased, damaged or malfunctioning aortic heart valve.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
The use of stents has improved management and outcomes of coronary artery disease, and clinical trials are attempting to prove the same will be true for superficial femoral artery disease. Randomized trials have shown favorable results for self-expanding nitinol stents compared with balloon angioplasty. A new report seeks to test this treatment in a real-world population of patients enrolled in an observational registry.
Cigna Corporation has reinstated coverage of the Ambulatory Cardiac Telemetry (ACT) service and is retroactively effective as of June 15, 2014.
Lombard Medical Inc., a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA), today announced that its lead product, Aorfix, an endovascular stent graft to treat AAA, has received approval from the Japanese Ministry of Health, Labour and Welfare. Commercial sales will follow reimbursement approval. Aorfix will be exclusively distributed by Medico's Hirata Inc. Japan is the world’s second-largest standalone EVAR market.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
The Cardiovascular Cell Therapy Research Network (CCTRN) has selected Cytori Therapeutics Inc. to supply adipose-derived regenerative cells (ADRC) for a clinical trial aimed at evaluating the safety and feasibility of treating patients with left ventricular assist devices (LVADs). The CCTRN is supported by grants from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This trial, named CELLVAD-ADRC, will explore outcomes following administration of a regenerative cell preparation from adipose tissue into the patient’s heart muscle 60 to 90 days after placement of an LVAD.
Healthcare organizations looking to implement low dose protocols for computed tomography (CT) exams on all scanners, regardless of disparate locations, can now benefit from SafeCT Enterprise from Medic Vision. The solution will be displayed at RSNA 2014.
Cardiothoracic and Vascular Surgeons became the first in Texas to implant the Solo Smart Aortic Pericardial Heart Valve. Faraz Kerendi, M.D. and Stephen J. Dewan M.D., performed the procedure at Heart Hospital of Austin.